Reactions 1680, p294 - 2 Dec 2017
Wound healing failure: case report
A 51-year-old man developed wound healing failure
following the therapy with ramucirumab.
The man had metastatic stage IV lung adenocarcinoma. He
had received carboplatin, pemetrexed and bevacizumab.
However, due to disease progression, his medication was
altered to docetaxel and ramucirumab 10 mg/kg [route not
stated]. After two weeks of cycle 1, he underwent right jugular
port placement for the adenocarcinoma. Six days later, he
received another cycle of docetaxel and ramucirumab using a
peripheral access, since the chest wall site was noted not to
have healed. A third cycle of docetaxel and ramucirumab was
administered peripherally after one month of the port
placement. The chest incision site was noted to be tender with
incomplete healing. One week later, the port site and
venotomy incisions were not well apposed, with mild exudate
from the incision. It was then revealed that the wound healing
failure was due to the ramucirumab therapy.
The man’s ramucirumab therapy was discontinued. He then
received treatment with cefalexin. After one month, there was
slight improvement in the port reservoir site, but the venotomy
site was open and had not improved. The port was then
removed and then a new port placed on the left side.
Author comment: "In this case, the poor wound healing
likely represents an adverse effect of ramucirumab".
Zhan C, et al. Wound Healing Failure Following Venous Access Chest Port
Placement Associated with Ramucirumab Therapy. Cardiovascular and
Interventional Radiology 40: 1804-1806, No. 11, Nov 2017. Available from: URL:
http://doi.org/10.1007/s00270-017-1752-8 - USA
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved